RobertSNegrinMD

Hematology • Stanford, CA

Professor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center

Join to view full profile

Dr. Negrin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Negrin's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-724-6182

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Neonatal-Perinatal Medicine, 1988 - 1989
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1987 - 1988
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1984 - 1987
Harvard Medical SchoolClass of 1984

Certifications & Licensure

CA State Medical License 1985 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation Start of enrollment: 2004 Jun 01
Unknown status
Phase 1
Bone Marrow Grafting for Leukemia and Lymphoma
ENROLLING_BY_INVITATION
Transplantation for Patients With Chronic Lymphocytic Leukemia Start of enrollment: 1996 Nov 01
Completed
Not Applicable
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies Start of enrollment: 1992 Sep 01
Completed
Not Applicable
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma Start of enrollment: 2003 Oct 01
Completed
Not Applicable
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL Start of enrollment: 2009 Aug 01
Completed
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Start of enrollment: 2011 Sep 01
Completed
Phase 1, Phase 2
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
COMPLETED
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

Durable reconstitution of sinonasal epithelium by transplant of CFTR gene corrected airway stem cells.
Dawn T Bravo, Sriram Vaidyanathan, Jeannette Baker, Vrishti Sinha, Esmond Tsai
Biorxiv. 2025-01-26
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
Everett Meyer, Anna Pavlova, Alejandro Villar-Prados, Cameron S Bader, Bryan Xie
Blood. 2025-01-10
6 citations
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Hrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, Nikeshan Jeyakumar, Mark Hamilton
Blood. 2024-10-17

Abstracts/Posters

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming
Robert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Robert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Activation of Regulatory T Cells with IL-2 and TNF-_ to Promote Homing to the Gut and to Improve Acute GvHD Prevention
Robert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

How to Peer Review a Scientific Paper
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Volunteering Your Skills Overseas
60th American Society of Hematology Annual Meeting - 11/30/2018

Other

Preparative regimens for hematopoietic cell transplantation
Negrin RS
http://www.uptodate.com/contents/preparative-regimens-for-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2013-02-25
Oral toxicity associated with chemotherapy
Negrin RS, Bedard J, Toljanic JA
http://www.uptodate.com/contents/oral-toxicity-associated-with-chemotherapy
UpToDate, Wolters Kluwer Health - 2012-12-21
Busulfan-induced pulmonary injury
Negrin RS, Russi EW
http://www.uptodate.com/contents/busulfan-induced-pulmonary-injury
UpToDate, Wolters Kluwer Health - 2012-08-13
Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy
Negrin RS, Schiffer CA
http://www.uptodate.com/contents/treatment-of-chronic-myeloid-leukemia-in-chronic-phase-after-failur
UpToDate, Wolters Kluwer Health - 2013-01-08
Treatment of chronic myeloid leukemia in blast crisis
Negrin RS, Schiffer CA
http://www.uptodate.com/contents/treatment-of-chronic-myeloid-leukemia-in-blast-crisis
UpToDate, Wolters Kluwer Health - 2013-01-15
Treatment of chronic myeloid leukemia in accelerated phase
Negrin RS, Schiffer CA
http://www.uptodate.com/contents/treatment-of-chronic-myeloid-leukemia-in-accelerated-phase
UpToDate, Wolters Kluwer Health - 2013-01-03
Interferon alpha for the treatment of chronic myeloid leukemia
Negrin RS, Schiffer CA
http://www.uptodate.com/contents/interferon-alpha-for-the-treatment-of-chronic-myeloid-leukemia
UpToDate, Wolters Kluwer Health - 2012-09-25
Initial treatment of chronic myeloid leukemia in chronic phase
Negrin RS, Schiffer CA
http://www.uptodate.com/contents/initial-treatment-of-chronic-myeloid-leukemia-in-chronic-phase
UpToDate, Wolters Kluwer Health - 2012-12-03
Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia
Negrin RS, Schiffer CA
http://www.uptodate.com/contents/clinical-use-of-tyrosine-kinase-inhibitors-for-chronic-myeloid-leuk
UpToDate, Wolters Kluwer Health - 2012-10-26
Hematopoietic cell transplantation in myelodysplastic syndromes
Negrin RS
http://www.uptodate.com/contents/hematopoietic-cell-transplantation-in-myelodysplastic-syndromes
UpToDate, Wolters Kluwer Health - 2013-01-09
Hematopoietic cell transplantation in chronic myeloid leukemia
Negrin RS
http://www.uptodate.com/contents/hematopoietic-cell-transplantation-in-chronic-myeloid-leukemia
UpToDate, Wolters Kluwer Health - 2012-10-10
Hematopoietic cell transplantation in chronic lymphocytic leukemia
Negrin RS, Rai KR
http://www.uptodate.com/contents/hematopoietic-cell-transplantation-in-chronic-lymphocytic-leukemia
UpToDate, Wolters Kluwer Health - 2012-06-27
Hematopoietic cell transplantation in aplastic anemia
Negrin RS
http://www.uptodate.com/contents/hematopoietic-cell-transplantation-in-aplastic-anemia
UpToDate, Wolters Kluwer Health - 2013-04-18
Supportive care after hematopoietic cell transplantation
Negrin RS
http://www.uptodate.com/contents/supportive-care-after-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2012-02-10
Malignancy after hematopoietic cell transplantation
Negrin RS
http://www.uptodate.com/contents/malignancy-after-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2012-08-13
Hematopoietic support after hematopoietic cell transplantation
Negrin RS
http://www.uptodate.com/contents/hematopoietic-support-after-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2012-02-08
Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation
Negrin RS
http://www.uptodate.com/contents/immunotherapy-for-the-prevention-and-treatment-of-relapse-following
UpToDate, Wolters Kluwer Health - 2013-03-22
Sources of hematopoietic stem cells
Negrin RS
http://www.uptodate.com/contents/sources-of-hematopoietic-stem-cells
UpToDate, Wolters Kluwer Health - 2013-01-18
Quality of life following hematopoietic cell transplantation
Negrin RS
http://www.uptodate.com/contents/quality-of-life-following-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2012-05-21
Kidney disease following hematopoietic cell transplantation
Negrin RS, Parikh C
http://www.uptodate.com/contents/kidney-disease-following-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2012-08-01
Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation
Negrin RS
http://www.uptodate.com/contents/treatment-and-prevention-of-hepatic-sinusoidal-obstruction-syndrome
UpToDate, Wolters Kluwer Health - 2012-12-03
Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation
Negrin RS, Bonis PA
http://www.uptodate.com/contents/pathogenesis-and-clinical-features-of-hepatic-sinusoidal-obstructio
UpToDate, Wolters Kluwer Health - 2012-11-02
Donor selection for hematopoietic cell transplantation
Negrin RS
http://www.uptodate.com/contents/donor-selection-for-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2013-02-26
Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children
Negrin RS, Khan S
http://www.uptodate.com/contents/hematopoietic-cell-transplantation-for-idiopathic-severe-aplastic-a
UpToDate, Wolters Kluwer Health - 2012-12-03
Treatment and prevention of post-transplant lymphoproliferative disorders
Negrin RS, Brennan DC, Jessup M
http://www.uptodate.com/contents/treatment-and-prevention-of-post-transplant-lymphoproliferative-dis
UpToDate, Wolters Kluwer Health - 2013-01-10
Join now to see all

Authored Content

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

Orca Bio Announces the Precision-T Phase 3 Study Is Open and Enrolling Patients at Transplant Centers Across the U.S.February 3rd, 2025
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
Join now to see all

Grant Support

Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
Role Of Regulatory T Cells In GVHD, Gvt, And Tolerance InductionNational Heart, Lung, And Blood Institute2010–2011
HematopoeticNational Cancer Institute2010–2011
NK Cells In GVHD And GVTNational Cancer Institute2008–2011
Training Program In Hematopoietic Cell TransplantationNational Heart, Lung, And Blood Institute2001–2011
Regulatory T Cells In Allogeneic TransplantationNational Heart, Lung, And Blood Institute2009–2010
Prog 8- Hematopoietic Cell Transplantation AndNational Cancer Institute2007–2009
Regulatory T Cells Which Allow GVT Without GVHDNational Heart, Lung, And Blood Institute2004–2008
Visualizing Tumors And Mechanisms Of Therapy In VivoNational Cancer Institute1999–2007
BMT Clinical Trial Network At StanfordNational Heart, Lung, And Blood Institute2002–2003
BMT Clinical Trial Netwrok At StanfordNational Heart, Lung, And Blood Institute2001